Market Overview - The biopharmaceutical sector increased by 0.36% compared to the previous trading day, with Jindike leading the gains [1] - The Shanghai Composite Index closed at 3864.18, down 0.15%, while the Shenzhen Component Index closed at 12907.83, up 1.02% [1] Stock Performance - Jindike (688670) saw a closing price of 30.90, with a significant increase of 20.00% and a trading volume of 192,400 shares, amounting to a transaction value of 572 million [1] - Rongchang Bio (688331) closed at 92.25, up 5.43%, with a trading volume of 68,800 shares and a transaction value of 635 million [1] - Sanofi (688336) closed at 68.39, up 4.59%, with a trading volume of 74,400 shares and a transaction value of 510 million [1] - Other notable performers include Olin Bio (616889) with a 4.43% increase and Hualan Bio (301207) with a 3.21% increase [1] Fund Flow Analysis - The biopharmaceutical sector experienced a net inflow of 20.94 million from institutional investors, while retail investors saw a net outflow of 57.02 million [2] - Jindike had a net inflow of 57.00 million from institutional investors, despite a net outflow of 19.76 million from retail investors [3] - Rongchang Bio also saw a net inflow of 32.94 million from institutional investors, with retail investors withdrawing 25.48 million [3]

Market Overview - The biopharmaceutical sector increased by 0.83% on November 25, with Jindike leading the gains [1] - The Shanghai Composite Index closed at 3870.02, up 0.87%, while the Shenzhen Component Index closed at 12777.31, up 1.53% [1] Top Gainers in Biopharmaceutical Sector - Jinke (688670) closed at 25.75, up 19.99% with a trading volume of 92,200 shares [1] - Hualan Biological (301207) closed at 23.33, up 11.25% with a trading volume of 250,500 shares [1] - Saiseng Pharmaceutical (300485) closed at 11.95, up 5.19% with a trading volume of 168,000 shares [1] - Other notable gainers include Bohui Innovation (300318) at 6.84 (+3.32%) and Dongbao Biological (300239) at 5.72 (+3.25%) [1] Market Capital Flow - The biopharmaceutical sector saw a net inflow of 40.88 million yuan from institutional investors, while retail investors experienced a net outflow of 147 million yuan [2] - The sector's overall capital flow indicates a strong interest from institutional investors despite retail selling pressure [2] Individual Stock Capital Flow - Jinke (688670) had a net inflow of 39.66 million yuan from institutional investors, while retail investors showed a net outflow of 13.72 million yuan [3] - Other stocks like Watson Bio (300142) and Hualan Bio (002007) also experienced significant net inflows from institutional investors, indicating positive sentiment [3] - Conversely, stocks like Dongbao Biological (300239) and Bohui Innovation (300318) faced net outflows from retail investors, suggesting mixed investor sentiment [3]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002773 证券简称：康弘药业 公告编号：2025-063 成都康弘药业集团股份有限公司 一．药品基本信息 药品名称：米拉贝隆缓释片 剂型：片剂 规格：50mg 适应症：成年膀胱过度活动症（OAB）患者尿急、尿频和/或急迫性尿失禁的对症治疗。 注册分类：化学药品4类 批准文号：国药准字H20255960 审批结论：根据《中华人民共和国药品管理法》及有关规定，经 关于公司收到药品注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 成都康弘药业集团股份有限公司（以下简称"公司"）于近日收到国家药品监督管理局签发的米拉贝隆缓 释片的《药品注册证书》（证书编号：2025S03430），批准注册。现将相关情况公告如下： 审查，本品符合药品注册的有关要求，批准注册，发给药品注册证书。 二．产品简介 米拉贝隆为选择性β3肾上腺素受体激动剂，通过作用于膀胱组织，使膀胱平滑肌松弛。 三．对公司的影响 本次米拉贝隆缓释片获批上市，丰富了公司的产品管线。 由于医药产品的生产销售情况可能受到国家政策、市场环境变 ...

（文章来源：证券日报） 证券日报网讯 11月24日晚间，康弘药业发布公告称，公司于近日收到国家药品监督管理局签发的米拉 贝隆缓释片的《药品注册证书》（证书编号：2025S03430），批准注册。 ...

Core Viewpoint - Kanghong Pharmaceutical has received the drug registration certificate for Mirabegron extended-release tablets from the National Medical Products Administration, indicating a significant regulatory approval for the company’s product [1] Company Summary - Kanghong Pharmaceutical (002773.SZ) has announced the approval of Mirabegron, a selective β3 adrenergic receptor agonist, which acts on bladder tissue to relax bladder smooth muscle [1]

Core Viewpoint - Kanghong Pharmaceutical has received the drug registration certificate for Mirabegron extended-release tablets from the National Medical Products Administration, marking a significant milestone for the company in the treatment of overactive bladder (OAB) [1] Company Summary - The approved drug, Mirabegron, is a selective β3 adrenergic receptor agonist that relaxes the bladder smooth muscle [1] - The indication for this approval is for the symptomatic treatment of adult patients with overactive bladder, specifically addressing symptoms such as urgency, frequency, and/or urge incontinence [1]

智通财经APP讯，康弘药业(002773.SZ)公告，公司近日收到国家药品监督管理局签发的米拉贝隆缓释片 的《药品注册证书》，批准注册。米拉贝隆为选择性β3肾上腺素受体激动剂，通过作用于膀胱组织， 使膀胱平滑肌松弛。 ...

格隆汇11月24日丨康弘药业(002773.SZ)公布，近日收到国家药品监督管理局签发的米拉贝隆缓释片的 《药品注册证书》（证书编号：2025S03430），批准注册。米拉贝隆为选择性β3肾上腺素受体激动 剂，通过作用于膀胱组织，使膀胱平滑肌松弛。 ...

格隆汇11月24日丨康弘药业(002773.SZ)公布，近日收到国家药品监督管理局签发的米拉贝隆缓释片的 《药品注册证书》（证书编号：2025S03430），批准注册。米拉贝隆为选择性β3肾上腺素受体激动 剂，通过作用于膀胱组织，使膀胱平滑肌松弛。 ...

证券代码：002773 证券简称：康弘药业 公告编号：2025-063 成都康弘药业集团股份有限公司 关于公司收到药品注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 成都康弘药业集团股份有限公司（以下简称"公司"）于近日收 到国家药品监督管理局签发的米拉贝隆缓释片的《药品注册证书》（证 书编号：2025S03430），批准注册。现将相关情况公告如下： 一． 药品基本信息 药品名称：米拉贝隆缓释片 适应症：成年膀胱过度活动症（OAB）患者尿急、尿频和/或急迫 性尿失禁的对症治疗。 注册分类：化学药品 4 类 批准文号：国药准字 H20255960 审批结论：根据《中华人民共和国药品管理法》及有关规定，经 审查，本品符合药品注册的有关要求，批准注册，发给药品注册证书。 剂型：片剂 规格：50mg 三． 对公司的影响 本次米拉贝隆缓释片获批上市，丰富了公司的产品管线。 由于医药产品的生产销售情况可能受到国家政策、市场环境变化 等因素影响，存在不确定性，敬请广大投资者谨慎决策，注意投资风 险。 特此公告。 成都康弘药业集团股份有限公司董事会 2025年 ...